About AVRO

AVROBIO, Inc., is a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene therapies to treat rare diseases following a single dose. AVROBIO's gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. AVROBIO is focused on the development of its gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Biological Product (except Diagnostic) Manufacturing

AVRO is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
DESC Xtrackers Russell 2000 Comprehensive Factor ETF 9.9 M 9934930 1,484 1484 0.01% 0.000101633 999 999
IBB iShares Nasdaq Biotechnology Index Fund 7.5 B 7.53828E+09 221 221 0.05% 0.0005 3.3 M 3296630
ITOT iShares Core S&P Total U.S. Stock Market ETF 20.7 B 2.06508E+10 3,543 3543 0.0% 0 392 K 392454
IWM iShares Russell 2000 ETF 42.3 B 4.22947E+10 1,985 1985 0.01% 0.0001 3.5 M 3505070
IWN iShares Russell 2000 Value ETF 8.7 B 8.68983E+09 1,350 1350 0.0% 0 269 K 269433
IWO iShares Russell 2000 Growth ETF 9.0 B 9.02135E+09 1,231 1231 0.01% 0.0001 1.2 M 1201150
IWV iShares Russell 3000 ETF 9.4 B 9.39954E+09 2,928 2928 0.0% 0 31 K 30993
BIB ProShares Ultra Nasdaq Biotechnology 234.5 M 2.34453E+08 236 236 0.02% 0.000188076 91 K 91382
UBIO Proshares UltraPro Nasdaq Biotechnology 31.1 M 3.11229E+07 228 228 0.01% 0.000121657 11 K 11448
URTY ProShares UltraPro Russell2000 93.3 M 9.3288E+07 1,995 1995 0.0% 1.89057E-05 6 K 5602
UWM ProShares Ultra Russell2000 162.7 M 1.62672E+08 1,995 1995 0.0% 3.2645E-05 12 K 11542